Renalytix Plc (NASDAQ:RNLX) Q4 2023 Earnings Call Transcript

James McCullough: I think there are lots of specific reasons. The VA system turned out to be substantially more complex than we could have imagined. We are still making progress with the VA system. But I think for us, we’re resetting expectations around the VA as a business segment. I do think it will eventually become a significant contributor. But as we’ve said in previous calls, the complexity of operating inside the VA system has been a bit of a surprise.

Yi Chen: Okay. So going forward, do you expect a steady growth in test volume from quarter-to-quarter? Or do you think there will be variations or fluctuations?

James Sterling: Yes. I’m anticipating growth from here. Go ahead, James.

James McCullough: No, go ahead, OJ. I apologize.

James Sterling: No, that’s the extent of it. Yes. So yes. It’s been pretty steady state the last few quarters and into this quarter, we are expecting a growth from here for a lot of the reasons that we talked about on this call, especially as we roll into the FDA version of the test later in this fiscal year. But that combined with changes that we’re also making on the sales and marketing front.

Yi Chen: Okay. Thank you.

Operator: [Operator Instructions] I show no further questions at this time. This concludes today’s conference call. Thank you for participating. Have a great day. You may now disconnect.